Image credit: Canva
Tumors that are missing, or have a deficiency of, SMARCB1 and SMARCA4 genes are often associated with aggressive cancers. Immunotherapy may help the body’s immune system attack the tumor cells. A clinical trial led by Mary Frances Wedekind Malone, D.O., Assistant Research Physician in the Pediatric Oncology Branch, is researching how well tiragolumab and atezolizumab work for these types of cancers. The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact Jo Hurtt at (240) 858-7012 or jo.hurtt@nih.gov.
Clinicaltrials.gov identifier: NCT05286801
NCI Protocol ID: IRB001578
Official Title: A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
